Scholar Rock (NASDAQ:SRRK) Insider Mo Qatanani Sells 7,989 Shares

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Mo Qatanani sold 7,989 shares of Scholar Rock stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total transaction of $371,728.17. Following the transaction, the insider directly owned 106,929 shares of the company’s stock, valued at approximately $4,975,406.37. This trade represents a 6.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Mo Qatanani also recently made the following trade(s):

• On Thursday, January 22nd, Mo Qatanani sold 14,898 shares of Scholar Rock stock. The shares were sold at an average price of $46.71, for a total transaction of $695,885.58.
• On Friday, January 16th, Mo Qatanani sold 8,406 shares of Scholar Rock stock. The stock was sold at an average price of $44.48, for a total transaction of $373,898.88.
• On Wednesday, January 14th, Mo Qatanani sold 13,112 shares of Scholar Rock stock. The shares were sold at an average price of $45.20, for a total transaction of $592,662.40.
• On Thursday, December 4th, Mo Qatanani sold 136,462 shares of Scholar Rock stock. The stock was sold at an average price of $45.21, for a total transaction of $6,169,447.02.

Scholar Rock Stock Performance

Shares of Scholar Rock stock traded up $0.46 on Friday, hitting $48.16. The stock had a trading volume of 759,358 shares, compared to its average volume of 997,790. The stock has a market cap of $4.91 billion, a price-to-earnings ratio of -15.29 and a beta of 0.67. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.41. Scholar Rock Holding Corporation has a twelve month low of $22.71 and a twelve month high of $49.82. The business’s 50 day moving average is $45.14 and its two-hundred day moving average is $38.30.

Hedge Funds Weigh In On Scholar Rock

Several hedge funds have recently bought and sold shares of SRRK. Three Seasons Wealth LLC raised its position in shares of Scholar Rock by 2.1% in the 4th quarter. Three Seasons Wealth LLC now owns 10,968 shares of the company’s stock valued at $483,000 after buying an additional 222 shares in the last quarter. IFP Advisors Inc increased its stake in Scholar Rock by 294.1% in the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after acquiring an additional 450 shares during the last quarter. Principal Financial Group Inc. increased its stake in Scholar Rock by 7.9% in the third quarter. Principal Financial Group Inc. now owns 6,214 shares of the company’s stock valued at $231,000 after acquiring an additional 456 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Scholar Rock by 151.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after purchasing an additional 525 shares in the last quarter. Finally, California State Teachers Retirement System lifted its stake in Scholar Rock by 0.9% during the second quarter. California State Teachers Retirement System now owns 62,372 shares of the company’s stock worth $2,209,000 after purchasing an additional 577 shares during the last quarter. 91.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

SRRK has been the topic of several recent research reports. Barclays increased their price objective on Scholar Rock from $45.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. BMO Capital Markets reaffirmed an “outperform” rating and set a $50.00 price target on shares of Scholar Rock in a research report on Friday, November 14th. Wolfe Research assumed coverage on shares of Scholar Rock in a report on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 price objective for the company. JPMorgan Chase & Co. raised their target price on shares of Scholar Rock from $46.00 to $47.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a research report on Thursday, January 22nd. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Scholar Rock has an average rating of “Buy” and a consensus price target of $51.14.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).